Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewFR 122047 hydrochloride is a selective cyclooxygenase-1 (COX-1) inhibitor (IC50 values are 0.028 and 65 μM for COX-1 and COX-2 respectively). Antiplatelet, analgesic and anti-inflammatory following oral administration in vivo.
分子量 | 459.99 |
公式 | C23H25N3O3S.HCl |
储存 | Desiccate at +4°C |
纯度 | ≥98% (HPLC) |
CAS Number | 130717-51-0 |
PubChem ID | 196840 |
InChI Key | YWMAVHIKOAOSFM-UHFFFAOYSA-N |
Smiles | Cl.COC1=CC=C(C=C1)C1=C(N=C(S1)C(=O)N1CCN(C)CC1)C1=CC=C(OC)C=C1 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
---|---|---|---|
溶解性 | |||
water | 4.6 | 10 |
以下数据基于产品分子量 459.99。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 21.74 mL | 108.7 mL | 217.4 mL |
0.5 mM | 4.35 mL | 21.74 mL | 43.48 mL |
1 mM | 2.17 mL | 10.87 mL | 21.74 mL |
5 mM | 0.43 mL | 2.17 mL | 4.35 mL |
参考文献是支持产品生物活性的出版物。
Dohi et al (1993) The anti-platelet actions of FR122047, a novel cyclooxygenase inhibitor. Eur.J.Pharmacol. 243 179 PMID: 8276067
Ochi et al (2000) The analgesic effect profile of FR122047, a selective cyclo-oxygenase-1 inhibitor, in chemical nociceptive models. Eur.J.Pharmacol. 391 49 PMID: 10720634
Ochi and Goto (2002) Differential effect of FR122047, a selective cyclo-oxygenase-1 inhibitor, in rat chronic models of arthritis. Br.J.Pharmacol. 135 782 PMID: 11834626
Tanaka et al (1994) Antiplatelet agents based on cyclooxygenase inhibition without ulcerogenesis. Evaluation and synthesis of 4,5-bis(4-methoxyphenyl)-2-substituted-thiazoles. J.Med.Chem. 37 1189 PMID: 8164261
If you know of a relevant reference for FR 122047 hydrochloride, please let us know.
关键词: FR 122047 hydrochloride, FR 122047 hydrochloride supplier, Cyclooxygenase, COX-1, inhibitors, inhibits, Oxygenases, Oxidases, FR122047, hydrochloride, 1507, Tocris Bioscience
引用文献是使用了 Tocris 产品的出版物。 FR 122047 hydrochloride 的部分引用包括:
Tunaru et al (2016) Arachidonic acid metabolite 19(S)-HETE induces vasorelaxation and platelet inhibition by activating prostacyclin (IP) receptor. PLoS One 11 e0163633 PMID: 27662627
Tunaru et al (2012) Castor oil induces laxation and uterus contraction via ricinoleic acid activating prostaglandin EP3 receptors. PLoS One 109 9179 PMID: 22615395
Passafaro et al (2011) Cholinergic Autoantibodies from Primary Sjögren's Syndrome Inhibit Mucin Production via Phospholipase C and Cyclooxygenase-2 In the Rat Submandibular Gland. J Virol 8 138 PMID: 22013477
Lu et al (2013) Aspirin minimized the pro-metastasis effect of sora. and improved survival by up-regulating HTATIP2 in hepatocellular carcinoma. J Biol Chem 8 e65023 PMID: 23741443
Chia et al (2011) Protection of protease-activated receptor 2 mediated vasodilatation against angiotensin II-induced vascular dysfunction in mice. BMC Pharmacol 11 10 PMID: 21955547
Ray et al (2004) Cyclooxygenase-1 and -2 are required for production of infectious pseudorabies virus. Proc Natl Acad Sci U S A 78 12964 PMID: 15542648
您是否知道使用了 Tocris FR 122047 hydrochloride 的优秀论文? 请告知我们.
目前没有该产品的评论。 Be the first to review FR 122047 hydrochloride and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.